Medical approaches to preservation of fertility in female cancer patients

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 3, 2011, Pages 387-396

  Del Mastro, Lucia ^a   Giraudi, Sara ^a   Levaggi, Alessia ^a   Pronzato, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

chemotherapy; gonadotropin releasing hormone analogues; iatrogenic menopause; infertility

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; BUSERELIN; BUSULFAN; CETUXIMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; IMATINIB; IRINOTECAN; LETROZOLE; LEUPRORELIN; MELPHALAN; METHOTREXATE; NITROSOUREA; OXALIPLATIN; PREDNISONE; PROCARBAZINE; TRASTUZUMAB; TRIPTORELIN; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AMENORRHEA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG EFFECT; DRUG MECHANISM; EARLY MENOPAUSE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONE RELEASE; HUMAN; MULTIPLE CYCLE TREATMENT; OOCYTE; OVARIAN PRESERVATION; OVARY FUNCTION; PREGNANCY; REVIEW;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; CRYOPRESERVATION; FEMALE; FERTILITY; GONADOTROPIN-RELEASING HORMONE; HUMANS; NEOPLASMS; OVARY; PRIMARY OVARIAN INSUFFICIENCY;

EID: 79251471160     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.522568     Document Type: Review

References (75)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010. CA Cancer J Clin 2010;60:277-300
2. Berkowitz GS, Skovron ML, Lapinski RH, et al. Delayed childbearing and the outcome of pregnancy. N Engl J Med 1990;322:639-64
3. Rivkees AS, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988;259:2123-25
4. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990;61:861-5
5. Ataya K, Rao LV, Lawrence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72
6. Del Mastro L, Catzeddu T, Venturini M. Infertility and pregnancy after breast cancer: current knowledge and future perspectives. Cancer Treat Rev 2006;32:417-22
7. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74
8. Pujol P, Hilsenbeck SG, Chamness GC, et al. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994;75:1601-6
9. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000;320:474-8
10. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003;21:28-34
11. Ives A, Saunders C, Bulgara M, et al. Pregnancy after breast cancer: population-based study. BMJ 2007;334:194-8
12. Blakely LJ, Buzdarm AU, Lozada JA, et al. Effects of pregnancy after treatment for breast cancer on survival and risk of recurrence. Cancer 2004;100:465-9
13. Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 1999;85:2424-32
14. Gelber S, Coates AS, Goldhirsch A, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 2001;19:1671-5
15. Kroman N, Jensen MB, Melbye M, et al. Should women be advised against pregnancy after breast cancer treatment? Lancet 1997;350:319-22
16. Von Schoultz E, Johansson H, Wilking N, et al. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995;13:430-4
17. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: healthy mother effect. Am J Obstet Gynecol 1994;70:818-23
18. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990;65:847-50
19. Malamos NA, Stathopoulos GP, Keramopoulos A, et al. Pregnancy and offspring after the appearance of breast cancer. Oncology 1996;53:471-5
20. Ariel IM, Kempner R The prognosis of patients who become pregnant after mastectomy for breast cancer. Int Surg 1989;74:185-7
21. Mueller BA, Simon MS, Deapen D, et al. Childbearing and survival after breast carcinoma in young women. Cancer 2003;98:1131-40
22. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertilita preservation in cancer patients. J Clin Oncol 2006;18:2917-31
23. United Kingdom Children's Cancer Study Group (UKCCSG). Subfertility Risk Consensus Document, 2005. Available from: http://www.ukccsg.org
24. Children's Oncology Group (COG). Longterm follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, 2004. Available from: http://survivorshipguidelines.org
25. Scottish Intercollegiate Guidelines Network. Long-term follow-up of survivors of childhood cancer, 2005. Available from: http://www.sign.ac.uk
26. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:1086-94
27. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70
28. Grigg A. The impact of conventional and high-dose therapy for lymphoma on fertility. Clin Lymphoma 2004;5:84-8
29. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;34:12-17
30. Meistrich ML, Vassilopoulou-Sellin R, Lipshultz LI. Gonadal dysfunction, cancer: principles &practice of oncology. 7th edition. Lippincott Williams &Wilkins, Philadelphia, PA; 2005. p. 2560-72
31. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-18
32. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29
33. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005;97:1724-33
34. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16:2651-8
35. Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010;362:2053-65
36. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13
37. Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin and cyclophosfamide followed by docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009;113:315-20
38. Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy- induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575-9
39. Del Mastro L, Venturini M, Sertoli MR, et al. Amenorrhea indiced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997;43:183-90
40. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J Clin Oncol 2002;20:4628-35
41. Braverman AS, Sawhney H, Tendler A, et al. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT-) induced amenorrhea in breast cancer (BC). Proc Am Soc Clin Oncol 2002;21:42a
42. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64-73
43. Themmen APN. Anti-Mullerian hormone: its role in follicular growth initiation and survival and as ovarian reserve marker. J Natl Cancer Inst Monogr 2005;34:18-21
44. de Vet A, Laven JS, de Jong FH, et al. Anti-Mullerian hormone serum levels: a putative mark of ovarian aging. Fertil Steril 2002;77:357-62
45. Bath LE, Wallace WH, Shaw MP, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368-74
46. Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr 2005;34:57-9
47. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26:2630-5
48. Colleoni M, Bonetti M, Coates A, et al. Early start of adjuvant chemotherapy may improve out come for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol 2000;18:584-90
49. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early stage breast cancer. N Engl J Med 1996;334:1356-61
50. Huang JY, Tulandi T, Holzer H, et al. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008;89:567-72
51. Ataya KM, McKanna JA, Weintraub AM, et al. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985;45:3651-6
52. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044-54
53. Kitajima Y, Endo T, Nagasawa K, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006;147:725-48
54. Imai A, Sugiyama M, Furui T, et al. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007;63:102-6
55. Beek-Fruchter R, Weiss A, Shalev E. GnRH against therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.Hum Reprod Update 2008;14:553-61
56. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987;19:159-62
57. Pereyra Pacheco B, Mendez Ribas JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-7
58. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005;34:40-3
59. Franke HR, Smit WM, Vermes I. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynecol Endocrinol 2005;20:274-8
60. Dann EJ, Epelbaum R, Avivi I, et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005;20:2247-9
61. Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7
62. Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006;17:74-8
63. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23
64. Giuseppe L, Attilio G, Edoardo DN, et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007;12:141-7
65. Castelo-Branco C, Nomdedeu B, Camus A, et al. Use of gonadotropin- releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 2007;87:702-5
66. Blumenfeld Z, Avivi I, Eckman A, et al. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008;89:166-73
67. Huser M, Crha I, Ventruba P, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 2008;23:863-8
68. Fox KR, Scialla J, Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol 2003;22:abstract 50
69. Urruticoechea A, Arnedos M, Walsh G, et al. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008;110(3):411-16
70. Hackshaw A, Baum M, Fornander T, et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009;101:341-9
71. Sverrisdottir A, Nystedt M, Johansson H, et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561-7
72. Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7
73. Gerber B, Stehle H, Ricardo F, et al. ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol 2009;27(15S):abstract 526
74. Leonard RC, Adamson D, Anderson R, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010;28(15S):abstract 590
75. Del Mastro L, Boni L, Michelotti A, et al. Role of luteinizing hormone-releasing hormone analog (LH-Rha) Triptorelin in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 2010;28(15S):abstract 528